¹⁷⁷Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer.

ABSTRACT: ¹⁷⁷Lu-PSMA radioligand therapy (LuPRLT) is mainly used for patients with metastatic castration-resistant prostate cancer who are resistant to established drugs. This study describes LuPRLT, either LuPSMA I&T or LuPSMA RLT-617, for 45 patients with predominant lymph node metastatic prostate cancer (LNM PC). Thirty-five patients had LNM and ten patients had LNM and one or two bone metastases. Before LuPRLT, the patients had prostate specific antigen (PSA) of median 18 µg/l (interquartile range (IQR): 3.3-39). LuPRLT was given with a cumulative injected ¹⁷⁷Lu activity of median 14.5 GBq (IQR: 12.2-20.4). Maximum percentage decline of PSA was median 92% (IQR: 70-99). Thirty-five patients with only LNM had a better overall survival (OS) than ten patients with LNM and one o

SUBMITTER: von Eyben FE 

PROVIDER: S-EPMC6497435 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature